Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Company Overview

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Key Stats

• Today's Range: $1.36 to $1.52
• 50-Day Range: $1.10 to $1.49
• 52-Week Range: $1.02 to $3.50
• Volume: 15,883 shs
• Average Volume: 186,239 shs
• Market Capitalization: $4.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Lixte Biotechnology Stock Analysis - MarketRank™

Lixte Biotechnology scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lixte Biotechnology.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lixte Biotechnology is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lixte Biotechnology is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lixte Biotechnology has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.95% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently decreased by 25.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lixte Biotechnology does not currently pay a dividend.

Dividend Growth

Lixte Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.95% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently decreased by 25.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Lixte Biotechnology has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lixte Biotechnology this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.80% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.10% of the stock of Lixte Biotechnology is held by institutions.

LIXT Stock Analysis - Frequently Asked Questions

How have LIXT shares performed this year?

Lixte Biotechnology's stock was trading at $2.03 at the beginning of 2025. Since then, LIXT stock has decreased by 32.0% and is now trading at $1.38.
View the best growth stocks for 2025 here.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.29) earnings per share for the quarter.

When did Lixte Biotechnology's stock split?

Shares of Lixte Biotechnology reverse split on the morning of Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

Lixte Biotechnology (LIXT) raised $7 million in an initial public offering on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

Who are Lixte Biotechnology's major shareholders?

Lixte Biotechnology's top institutional shareholders include FNY Investment Advisers LLC (3.40%). Insiders that own company stock include Rene Bernards, Der Baan Bastiaan Jeroen Van, Eric Forman and Regina Brown.
View institutional ownership trends.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lixte Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 5/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIXT
• CIK: 1335105
• Web: www.lixte.com
• Phone: (631) 830-7092
• Fax: 631-982-5050
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,090,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,562.77%
• Return on Assets: -130.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 6.27

Miscellaneous

• Outstanding Shares: 3,151,000
• Free Float: 1,916,000
• Market Cap: $4.35 million
• Optionable: Not Optionable
• Beta: 0.40